as 03-28-2025 4:00pm EST
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Founded: | 1856 | Country: | United Kingdom |
Employees: | N/A | City: | N/A |
Market Cap: | 12.3B | IPO Year: | 1999 |
Target Price: | $27.00 | AVG Volume (30 days): | 744.3K |
Analyst Decision: | Hold | Number of Analysts: | 3 |
Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
EPS: | 0.47 | EPS Growth: | 56.15 |
52 Week Low/High: | $23.65 - $31.72 | Next Earning Date: | 02-25-2025 |
Revenue: | $5,810,000,000 | Revenue Growth: | 4.70% |
Revenue Growth (this year): | 6.42% | Revenue Growth (next year): | 5.03% |
SNN Breaking Stock News: Dive into SNN Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Simply Wall St.
12 days ago
Simply Wall St.
17 days ago
GlobeNewswire
18 days ago
GlobeNewswire
19 days ago
GlobeNewswire
23 days ago
Simply Wall St.
23 days ago
TipRanks
24 days ago
The information presented on this page, "SNN Smith & Nephew SNATS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.